BILAG

AcronymDefinition
BILAGBritish Isles Lupus Assessment Group
BILAGBritish Isles Lupus Activity Group
References in periodicals archive ?
BILAG A flare was significantly reduced compared to placebo with atacicept 75 mg (p=0.
A decrease from 23% to 11% in the frequency of patients experiencing a new BILAG A flare (which would indicate a severe flare of lupus disease activity) or more than one new BILAG B flare (which would indicate a moderate flare of disease activity).
The SRI defines patient response as an improvement in SELENA SLEDAI score of 4 points or greater, with no clinically significant BILAG worsening and no clinically significant worsening in Physician's Global Assessment.
30 points or more from baseline); (3) no new BILAG A organ domain score (which indicates a severe flare of lupus disease activity) and no more than one new BILAG B organ domain score (which indicates a moderate flare of disease activity).
15,18-20) In addition to work being performed in clinics by international groups, such as the SLICC (Systemic Lupus International Collaborating Clinics), the EULAR (European League Against Rheumatism) group, and a group chartered by the Lupus Foundation of America [which is working to optimize flare measurements and using both the SLEDAI (Systemic Lupus Erythematosus Disease Activity Index) and the BILAG (British Isles Lupus Assessment Group) instruments], data from recent industry-sponsored clinical trials support increased understanding of the strengths and weaknesses of each outcome measure.
30 points or more from baseline); and (3) no new BILAG A organ domain score (which indicates a severe flare of lupus disease activity) and no more than one new BILAG B organ domain score (which indicates a moderate flare of disease activity).
The SLE Responder Index defines patient response as an improvement in SELENA SLEDAI score of 4 points or greater, with no clinically significant BILAG worsening and no clinically significant worsening in Physician's Global Assessment.
5 mg hCDRl and BILAG as the measure for the primary efficacy endpoint.
The BLISS-52 patient response rate was based on the SLE Responder Index (SRI), which defines patient response by an improvement in SELENA SLEDAI score of 4 points or greater, with no clinically significant BILAG worsening, and no clinically significant worsening in Physician's Global Assessment.
The risk of having 1 BILAG A (severe flare) or more than 1 BILAG B (moderate flare) organ domain score was reduced by 42% in the 10 mg/kg belimumab treatment group and by 13% in the 1 mg/kg treatment group vs.
The advantage of using BILAG as compared to other assessment methods is that it allows each organ system to be evaluated individually.
Nasdaq:BIIB) announced today that a Phase II/III study of Rituxan([R])(rituximab) for systemic lupus erythematosus (SLE, commonly called lupus) did not meet its primary endpoint defined as the proportion of Rituxan treated patients who achieved a major clinical response (MCR) or partial clinical response (PCR) measured by BILAG, a lupus activity response index, compared to placebo at 52 weeks.